← Eichor
Study identifier: NCT06665997 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

Condition: Sickle Cell Disease (SCD) · Vaso-Occlusive Pain Episode in Sickle Cell Disease  ·  Sponsor: University of Pennsylvania

PhasePhase 4
Planned participants65
Who can joinFemale, 18 Years to 50 Years
Healthy volunteersNo

About this study

This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease. Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.

This description comes directly from the study's public registry record.

Talk to the study team

Arden McAllister, MPH  ·  267-785-8044  ·  arden.mcallister@pennmedicine.upenn.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Emory UniversityAtlanta, Georgia, United StatesNot Yet Recruiting
Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06665997